Cardiol Therapeutics (CRDL) Other financing activities (2020 - 2026)

Cardiol Therapeutics (CRDL) posted Other financing activities of -$901571.7 for Q1 2026, down 1512.28% on a QoQ basis from $63838.1 in Q2 2024.

Cardiol Therapeutics (CRDL) Other financing activities (2020 - 2026) Analysis & Trends

Cardiol Therapeutics' Other financing activities history runs 4 years deep, the most recent figure standing at -$901571.7 for Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to -$901571.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$837733.6 (changed N/A YoY) and the FY2021 annual result came in at $2.3 million, up 1551.11% from the prior year.
Other financing activities was -$901571.7 for Q1 2026 at Cardiol Therapeutics, down from $63838.1 in the prior quarter.
Across five years, Other financing activities topped out at $66936.4 in Q1 2024 and bottomed at -$901571.7 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Cardiol Therapeutics	134.05 Mn	134.05 Mn	-

Download Data